AEGERION PHARMACEUTICALS

This website has been established to provide general information related to the proposed settlement ("Settlement") of the action captioned KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al., No. 1:14-cv-10105-MLW. The capitalized terms used on this website, and not otherwise defined, shall have the same meanings ascribed to them in the Stipulation of Settlement (the "Stipulation") dated January 17, 2017, which can be found and downloaded by clicking on the Case Documents tab above... The Settlement Amount of $22.25 million and any interest earned thereon is the "Settlement Fund." The Settlement Fund, less all taxes, approved costs, fees, and expenses (the "Net Settlement Fund") shall be distributed to Class Members who submit timely and valid Proof of Claim forms to the Claims Administrator ("Authorized Claimants"). The Plan of Allocation provides that you will be eligible to participate in the distribution of the Net Settlement Fund only if you have an overall..

Also known as: Aegerion Pharmaceuticals, Inc., Aegerion Securities Litigation

Primary location: College Station United States